(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.61%) $83.34
(-1.16%) $1.619
(0.02%) $2 347.70
(0.93%) $27.51
(0.17%) $923.70
(-0.07%) $0.934
(-0.04%) $11.02
(-0.11%) $0.800
(0.00%) $92.17
2.53% INR 1 131.30
Live Chart Being Loaded With Signals
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India...
Stats | |
---|---|
Tagesvolumen | 1.51M |
Durchschnittsvolumen | 2.61M |
Marktkapitalisierung | 662.87B |
EPS | INR0 ( 2024-02-11 ) |
Nächstes Ertragsdatum | ( INR14.00 ) 2024-05-25 |
Last Dividend | INR3.00 ( 2023-02-17 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 23.95 |
ATR14 | INR1.269 (0.11%) |
Volumen Korrelation
Aurobindo Pharma Limited Korrelation
10 Am meisten positiv korreliert | |
---|---|
SETF10GILT.NS | 0.946 |
IZMO.NS | 0.936 |
ADORWELD.NS | 0.933 |
ANMOL.NS | 0.927 |
GTNTEX.NS | 0.92 |
ANURAS.NS | 0.918 |
FOCUS.NS | 0.918 |
TIIL.NS | 0.917 |
GISOLUTION.NS | 0.914 |
KIRLOSIND.NS | 0.913 |
10 Am meisten negativ korreliert | |
---|---|
STARTECK.NS | -0.883 |
GENESYS.NS | -0.878 |
EASTSILK.NS | -0.871 |
SEYAIND.NS | -0.871 |
ORTINLAB.NS | -0.864 |
DEEPINDS.NS | -0.862 |
GRMOVER.NS | -0.859 |
KOHINOOR.NS | -0.856 |
CLNINDIA.NS | -0.853 |
ESABINDIA.NS | -0.852 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Aurobindo Pharma Limited Korrelation - Währung/Rohstoff
Aurobindo Pharma Limited Finanzdaten
Annual | 2022 |
Umsatz: | INR246.17B |
Bruttogewinn: | INR133.24B (54.12 %) |
EPS: | INR32.90 |
FY | 2022 |
Umsatz: | INR246.17B |
Bruttogewinn: | INR133.24B (54.12 %) |
EPS: | INR32.90 |
FY | 2022 |
Umsatz: | INR233.67B |
Bruttogewinn: | INR132.26B (56.60 %) |
EPS: | INR45.19 |
FY | 2021 |
Umsatz: | INR245.58B |
Bruttogewinn: | INR146.55B (59.68 %) |
EPS: | INR91.05 |
Financial Reports:
No articles found.
Aurobindo Pharma Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR3.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.150 | 2001-09-12 |
Last Dividend | INR3.00 | 2023-02-17 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 42 | -- |
Total Paid Out | INR38.23 | -- |
Avg. Dividend % Per Year | 0.47% | -- |
Score | 2.7 | -- |
Div. Sustainability Score | 4.12 | |
Div.Growth Potential Score | 3.14 | |
Div. Directional Score | 3.63 | -- |
Year | Amount | Yield |
---|---|---|
2001 | INR0 | 0.00% |
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR2.25 | 0.36% |
2019 | INR2.50 | 0.34% |
2020 | INR4.25 | 0.93% |
2021 | INR4.50 | 0.49% |
2022 | INR6.00 | 0.82% |
2023 | INR3.00 | 0.69% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TOUCHWOOD.NS | Dividend Junior | 2023-09-22 | Annually | 6 | 0.15% | |
PGIL.NS | Dividend Junior | 2023-09-01 | Annually | 17 | 1.08% | |
JINDALSAW.NS | Dividend Junior | 2023-06-13 | Annually | 22 | 1.62% | |
DEEPAKNTR.NS | Dividend Junior | 2023-07-27 | Annually | 14 | 0.25% | |
SKMEGGPROD.NS | Dividend Junior | 2023-08-30 | Sporadic | 21 | 0.95% | |
MGEL.NS | Dividend Junior | 2023-08-08 | Annually | 5 | 0.59% | |
HARSHA.NS | Dividend Junior | 2023-09-20 | Insufficient data to determine frequency | 2 | 0.09% | |
BDL.NS | Dividend Junior | 2023-09-20 | Semi-Annually | 7 | 1.17% | |
PTC.NS | Dividend Knight | 2023-09-20 | Annually | 21 | 6.06% | |
KDDL.NS | Dividend Junior | 2023-09-22 | Annually | 8 | 0.29% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.100 | 1.500 | 7.99 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.101 | 1.500 | 9.99 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 15.99 | 1.000 | 5.19 | 5.19 | [3 - 30] |
operatingCashFlowPerShareTTM | 51.10 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 25.58 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.548 | 1.000 | 4.20 | 4.20 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.148 | 1.000 | 9.03 | 9.03 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 23.93 | 1.000 | 7.68 | 0 | [1 - 100] |
returnOnEquityTTM | 0.101 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 25.58 | 2.00 | 1.474 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.398 | 1.500 | 0.0557 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 51.10 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.413 | 1.500 | -6.08 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.109 | 1.000 | 9.79 | 0 | [0.1 - 0.5] |
Total Score | 3.14 |
Aurobindo Pharma Limited
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.